Daiichi Sankyo initiates research into edoxaban

Daiichi Sankyo revealed this week that it has initiated an investigation into the efficacy of edoxaban regarding the reduction of recurrent venous thromboembolic (VTE) complications in deep-vein thrombosis (DVT) and pulmonary embolism (PE) patients.

The primary safety assessment of the trial has been outlined as major and clinically relevant non-major bleeding.

According to previous research highlighted by the organisation, 750,000 people in the UK, France, Germany, Spain, Sweden and Italy are affected by VTE, with around 370,000 related deaths a year reported in these nations collectively.

Glenn Gormley, president of pharmaceutical development at the organisation, commented: “Daiichi Sankyo is proud to be advancing the research of Factor Xa inhibitors with edoxaban, which may help prevent deadly clots in various patient populations.”

Last month, Daiichi Sankyo highlighted the results of a study, which showed that Effient – the oral antiplatelet agent it co-developed with Eli Lilly and Ube Industries – is more cost-effective than other existing treatments.